$Reviva Pharmaceuticals Holdings, Inc.(RVPH)$ Reviva Pharmaceuticals Holdings (RVPH)
Roth MKM analyst reiterated a Buy rating on Reviva Pharmaceuticals Holdings today and set a price target of $3.00. The company’s shares closed last Friday at $0.55.
According to , Pachaiyappan has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -8.2% and a 37.8% success rate. Pachaiyappan covers the Healthcare sector, focusing on stocks such as Entrada Therapeutics Inc, Capricor Therapeutics, and Avidity Biosciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Reviva Pharmaceuticals Holdings with a $3.20 average price target, a 499.3% upside from current levels. In a report issued on September 29, Chardan Capital also initiated coverage with a Buy rating on the stock with a $2.00 price target.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
